AU2017267927B2 - Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction - Google Patents

Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction Download PDF

Info

Publication number
AU2017267927B2
AU2017267927B2 AU2017267927A AU2017267927A AU2017267927B2 AU 2017267927 B2 AU2017267927 B2 AU 2017267927B2 AU 2017267927 A AU2017267927 A AU 2017267927A AU 2017267927 A AU2017267927 A AU 2017267927A AU 2017267927 B2 AU2017267927 B2 AU 2017267927B2
Authority
AU
Australia
Prior art keywords
nicotine
cannabidiol
therapeutically effective
effective dose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017267927A
Other languages
English (en)
Other versions
AU2017267927A1 (en
Inventor
Jonnie R. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CV Sciences Inc
Original Assignee
CV Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Sciences Inc filed Critical CV Sciences Inc
Publication of AU2017267927A1 publication Critical patent/AU2017267927A1/en
Application granted granted Critical
Publication of AU2017267927B2 publication Critical patent/AU2017267927B2/en
Priority to AU2020256349A priority Critical patent/AU2020256349B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017267927A 2016-05-16 2017-05-02 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction Ceased AU2017267927B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020256349A AU2020256349B2 (en) 2016-05-16 2020-10-14 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662336990P 2016-05-16 2016-05-16
US62/336,990 2016-05-16
US15/426,617 2017-02-07
US15/426,617 US10653639B2 (en) 2016-05-16 2017-02-07 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
PCT/US2017/030558 WO2017200740A1 (en) 2016-05-16 2017-05-02 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020256349A Division AU2020256349B2 (en) 2016-05-16 2020-10-14 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Publications (2)

Publication Number Publication Date
AU2017267927A1 AU2017267927A1 (en) 2018-11-08
AU2017267927B2 true AU2017267927B2 (en) 2020-07-30

Family

ID=60297254

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017267927A Ceased AU2017267927B2 (en) 2016-05-16 2017-05-02 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
AU2020256349A Ceased AU2020256349B2 (en) 2016-05-16 2020-10-14 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020256349A Ceased AU2020256349B2 (en) 2016-05-16 2020-10-14 Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction

Country Status (8)

Country Link
US (2) US10653639B2 (enExample)
EP (2) EP3936129A1 (enExample)
JP (2) JP6816167B2 (enExample)
CN (1) CN109152773A (enExample)
AU (2) AU2017267927B2 (enExample)
CA (1) CA3021835C (enExample)
ES (1) ES2898342T3 (enExample)
WO (1) WO2017200740A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2018504B1 (en) * 2017-03-13 2018-09-21 Pharma Unlimited B V Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction
US11166910B2 (en) * 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
US11253473B2 (en) * 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
CN111789881A (zh) * 2019-04-04 2020-10-20 昆明医科大学 一种工业大麻提取物的用途
PL3946262T3 (pl) * 2019-08-30 2024-11-25 Evie Sa Wypełnione granulki, sposób ich wytwarzania i ich zastosowania
CN113100490A (zh) * 2021-05-21 2021-07-13 张家港外星人新材料科技有限公司 生物碱与酚反应合成物、雾化液、雾化弹及电子雾化器

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20150057341A1 (en) * 2013-08-22 2015-02-26 Stephen C. Perry Composition with Pharmacological Effect for Vaporizing and Method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
CA2075517C (en) 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US20020098264A1 (en) 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
GB0712308D0 (en) 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2229158T3 (en) * 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
DK2280687T3 (da) 2008-03-26 2019-05-27 Stichting Sanammad Tyggegummisammensætninger omfattende cannabinoider
GB2464752B (en) * 2008-10-24 2010-09-08 Anna Louise Bullus Chewing gum composition
MX374638B (es) 2009-01-20 2025-03-06 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.
DK2393487T3 (en) 2009-02-06 2017-01-23 Egalet Ltd Pharmaceutical compositions resistant to abuse
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
EP2723554A2 (en) * 2011-06-27 2014-04-30 IQ Tec Switzerland Gmbh Tool for manufacturing a preform assembly
US8623332B2 (en) 2011-07-06 2014-01-07 Fertin Pharma A/S Chewing gum having sustained release of nicotine
US20140328973A1 (en) 2011-12-22 2014-11-06 Bruno Provstgaard Nielsen Method of releasing nicotine from chewing gum
US20140166028A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP3448521B1 (en) * 2016-04-27 2023-10-25 APIRX Pharmaceutical USA, LLC Chewing gum composition comprising cannabinoids and nicotine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20150057341A1 (en) * 2013-08-22 2015-02-26 Stephen C. Perry Composition with Pharmacological Effect for Vaporizing and Method

Also Published As

Publication number Publication date
EP3458057A4 (en) 2020-02-05
JP6816167B2 (ja) 2021-01-20
AU2020256349B2 (en) 2022-03-31
US10653639B2 (en) 2020-05-19
JP7216697B2 (ja) 2023-02-01
EP3458057A1 (en) 2019-03-27
US20200230077A1 (en) 2020-07-23
EP3936129A1 (en) 2022-01-12
AU2020256349A1 (en) 2020-11-12
WO2017200740A1 (en) 2017-11-23
CN109152773A (zh) 2019-01-04
JP2021059575A (ja) 2021-04-15
US20170326126A1 (en) 2017-11-16
EP3458057B1 (en) 2021-09-08
CA3021835C (en) 2022-03-22
US11191736B2 (en) 2021-12-07
AU2017267927A1 (en) 2018-11-08
ES2898342T3 (es) 2022-03-07
JP2019514990A (ja) 2019-06-06
CA3021835A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
AU2020256349B2 (en) Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
US8858919B2 (en) Method of providing fast relief to a user of a nicotine chewing gum
US9884055B2 (en) Method of treating substance addictions
US8828361B2 (en) Tobacco alkaloid releasing chewing gum
US8623332B2 (en) Chewing gum having sustained release of nicotine
US11331310B2 (en) Method of treating cocaine addiction
CA3031523A1 (en) Chewing gum with improved delivery of cannabinoids
AU2019425173B2 (en) Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
JP2011057701A (ja) ニコチンチューインガム使用者に迅速な緩和をもたらす方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired